Effect of CD47 blockade on vascular inflammation
KU Jarr, R Nakamoto, BH Doan, Y Kojima… - … England Journal of …, 2021 - Mass Medical Soc
New England Journal of Medicine, 2021•Mass Medical Soc
Effect of CD47 Blockade on Vascular Inflammation Patients in a trial of the anti-CD47
antibody magrolimab for treatment of lymphoma underwent 18F-FDG PET–CT. Treatment
was found to reduce arterial 18F-FDG uptake, suggesting suppression of vascular
inflammation.
antibody magrolimab for treatment of lymphoma underwent 18F-FDG PET–CT. Treatment
was found to reduce arterial 18F-FDG uptake, suggesting suppression of vascular
inflammation.
Effect of CD47 Blockade on Vascular Inflammation
Patients in a trial of the anti-CD47 antibody magrolimab for treatment of lymphoma underwent 18F-FDG PET–CT. Treatment was found to reduce arterial 18F-FDG uptake, suggesting suppression of vascular inflammation.
The New England Journal Of Medicine